

## References

1. Bonvalot S, Raut CP, Pollock RE, Rutkowski P, Strauss DC, Hayes AJ, et al. Technical considerations in surgery for retroperitoneal sarcomas: position paper from E-Surge, a master class in sarcoma surgery, and EORTC-STBSG. *Ann Surg Oncol*. 2012;19(9):2981-91.
2. Swallow CJ, Strauss DC, Bonvalot S, Rutkowski P, Desai A, Gladdy RA, et al. Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group. *Ann Surg Oncol*. 2021;28(12):7873-88.
3. Dingley B, Fiore M, Gronchi A. Personalizing surgical margins in retroperitoneal sarcomas: an update. *Expert Review of Anticancer Therapy*. 2019;19(7):613-31.
4. Fairweather M, Gonzalez RJ, Strauss D, Raut CP. Current principles of surgery for retroperitoneal sarcomas. *J Surg Oncol*. 2018;117(1):33-41.
5. Gronchi A, Strauss DC, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, et al. Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group. *Annals of surgery*. 2016;263(5):1002-9.
6. Bertani E, Biffi R, Luca F, Crotti C, Testori A, Lazzaro G, et al. Primary and recurrent retroperitoneal soft tissue sarcoma: Prognostic factors affecting survival. *Journal of surgical oncology*. 2006;93(6):456-63.
7. Chiappa A, Bertani E, Pravettoni G, Zbar AP, Foschi D, Spinoglio G, et al. Aggressive Surgical Approach for Treatment of Primary and Recurrent Retroperitoneal Soft Tissue Sarcoma. *The Indian journal of surgery*. 2018;80(2):154-62.
8. Bonvalot S, Rivoire M, Castaing M, Stoeckle E, Le Cesne A, Blay JY, et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2009;27(1):31-7.
9. Cho CW, Lee KW, Park H, Kim HJ, Park JB, Choi Y-L, et al. Clinical benefit and residual kidney function of en bloc nephrectomy for perirenal retroperitoneal sarcoma. *Asia-Pacific journal of clinical oncology*. 2018;14(5):e465-e71.
10. Ng DWJ, Tan GHC, Chia CS, Chee SK, Quek R, Farid M, et al. Tumor biology remains the main determinant of prognosis in retroperitoneal sarcomas: a 14-year single-center experience. *Asia-Pacific journal of clinical oncology*. 2017;13(5):e458-e65.
11. Rossi CR, Varotto A, Pasquali S, Campana LG, Mocellin S, Sommariva A, et al. Patient outcome after complete surgery for retroperitoneal sarcoma. *Anticancer research*. 2013;33(9):4081-7.
12. Schwartz PB, Vande Walle K, Winslow ER, Abbott DE, Ethun CG, Cardona K, et al. Predictors of disease-free and overall survival in retroperitoneal sarcomas: A modern 16-year multi-institutional study from the United States sarcoma collaboration (USSC). *Sarcoma*. 2019;2019:5395131.
13. Smith HG, Panchalingam D, Hannay JAF, Smith MJF, Thomas JM, Hayes AJ, et al. Outcome following resection of retroperitoneal sarcoma. *The British journal of surgery*. 2015;102(13):1698-709.
14. Eroglu A, Kocaoglu H, Demirci S, Akgul H. Retroperitoneal soft tissue sarcoma: effect of hyperthermic total abdominal perfusion. *Tumori*. 1999;85(4):259-64.

15. Morizawa Y, Miyake M, Hori S, Nakai Y, Anai S, Tanaka N, et al. Extended resection including adjacent organs and Ki-67 labeling index are prognostic factors in patients with retroperitoneal soft tissue sarcomas. *World journal of surgical oncology*. 2016;14(1):43.
16. Gonzalez Lopez JA, Artigas Raventos V, Rodriguez Blanco M, Lopez-Pousa A, Bague S, Abellan M, et al. Differences between en bloc resection and enucleation of retroperitoneal sarcomas. *Cirugia espanola*. 2014;92(8):525-31.
17. Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. *Ann Surg*. 2003;238(3):358-70; discussion 70-1.
18. Abdelfatah E, Guzzetta AA, Nagarajan N, Schulick R, Wolfgang CL, Pawlik TM, et al. Long-term outcomes in treatment of retroperitoneal sarcomas: A 15 year single-institution evaluation of prognostic features. *Journal of surgical oncology*. 2016.
19. Spolverato G, Chiminazzo V, Lorenzoni G, Fiore M, Radaelli S, Sanfilippo R, et al. Oncological outcomes after major vascular resections for primary retroperitoneal liposarcoma. *European Journal of Surgical Oncology*. 2021;47(12):3004-10.
20. Kim KD, Lee KW, Lee JE, Hwang JA, Jo SJ, Kim J, et al. Postoperative Outcomes of Distal Pancreatectomy for Retroperitoneal Sarcoma Abutting the Pancreas in the Left Upper Quadrant. *Frontiers in Oncology*. 2021;11:792943.
21. Bonvalot S, Miceli R, Berselli M, Causeret S, Colombo C, Mariani L, et al. Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control. *Annals of surgical oncology*. 2010;17(6):1507-14.
22. Ikoma N, Roland CL, Torres KE, Chiang Y-J, Mann GN, Hunt KK, et al. Concomitant organ resection does not improve outcomes in primary retroperitoneal well-differentiated liposarcoma: A retrospective cohort study at a major sarcoma center. *Journal of surgical oncology*. 2018;117(6):1188-94.
23. Keung EZ, Hornick JL, Bertagnolli MM, Baldini EH, Raut CP. Predictors of outcomes in patients with primary retroperitoneal dedifferentiated liposarcoma undergoing surgery. *Journal of the American College of Surgeons*. 2014;218(2):206-17.
24. van Doorn RC, Gallee MP, Hart AA, Gortzak E, Rutgers EJ, van Coevorden F, et al. Resectable retroperitoneal soft tissue sarcomas. The effect of extent of resection and postoperative radiation therapy on local tumor control. *Cancer*. 1994;73(3):637-42.
25. Swallow CJ, Macneill AJ, Gronchi A, Callegaro D, Fiore M, Miceli R, et al. Postoperative Morbidity after Radical Resection of Primary Retroperitoneal Sarcoma. *Annals of surgery*. 2018;267(5):959-64.
26. Tseng WH, Martinez SR, Chen SL, Bold RJ, Canter RJ, Tamurian RM. Contiguous organ resection is safe in patients with retroperitoneal sarcoma: An ACS-NSQIP analysis. *Journal of surgical oncology*. 2011;103(5):390-4.
27. Judge SJ, Lata-Arias K, Yanagisawa M, Darrow MA, Monjazebe AM, Kirane AR, et al. Morbidity, mortality and temporal trends in the surgical management of retroperitoneal sarcoma: An ACS-NSQIP follow up analysis. *Journal of surgical oncology*. 2019;120(4):753-60.
28. Kiviniemi H, Laitinen S, Makela J. Prognostic factors predicting survival in the treatment of retroperitoneal sarcoma. *European Journal of Surgical Oncology*. 2000;26(6):552-5.
29. Turner BT, Hampton L, Schiller D, Mack LA, Robertson-More C, Li H, et al. Neoadjuvant radiotherapy followed by surgery compared with surgery alone in the

- treatment of retroperitoneal sarcoma: a population-based comparison. *Current oncology (Toronto, Ont)*. 2019;26(6):e766-e72.
30. Wu Y-X, Liu J-Y, Liu J-J, Yan P, Tang B, Cui Y-H, et al. A retrospective, single-center cohort study on 65 patients with primary retroperitoneal liposarcoma. *Oncology letters*. 2018;15(2):1799-810.
  31. Adam MA, Moris D, Behren S, Nussbaum DP, Jawitz O, Turner M, et al. Hospital volume threshold for the treatment of retroperitoneal sarcoma. *Anticancer research*. 2019;39(4):2007-14.
  32. Bagaria SP, Chang Y-H, Gray RJ, Ashman JB, Attia S, Wasif N. Improving Long-Term Outcomes for Patients with Extra-Abdominal Soft Tissue Sarcoma Regionalization to High-Volume Centers, Improved Compliance with Guidelines or Both? *Sarcoma*. 2018;2018:8141056.
  33. Bagaria SP, Neville M, Gray RJ, Gabriel E, Ashman JB, Attia S, et al. The Volume-Outcome Relationship in Retroperitoneal Soft Tissue Sarcoma: Evidence of Improved Short- and Long-Term Outcomes at High-Volume Institutions. *Sarcoma*. 2018;2018:3056562.
  34. Berger NG, Silva JP, Mogal H, Clarke CN, Bedi M, Charlson J, et al. Overall survival after resection of retroperitoneal sarcoma at academic cancer centers versus community cancer centers: An analysis of the National Cancer Data Base. *Surgery (United States)*. 2018;163(2):318-23.
  35. Gutierrez JC, Perez EA, Moffat FL, Livingstone AS, Franceschi D, Koniaris LG. Should soft tissue sarcomas be treated at high-volume centers? An analysis of 4205 patients. *Annals of surgery*. 2007;245(6):952-8.
  36. Kalaiselvan R, Malik AK, Rao R, Wong K, Ali N, Griffin M, et al. Impact of centralization of services on outcomes in a rare tumour: Retroperitoneal sarcomas. *European journal of surgical oncology*. 2019;45(2):249-53.
  37. Keung EZ, Chiang Y-J, Cormier JN, Torres KE, Hunt KK, Feig BW, et al. Treatment at low-volume hospitals is associated with reduced short-term and long-term outcomes for patients with retroperitoneal sarcoma. *Cancer*. 2018;124(23):4495-503.
  38. Lazarides AL, Kerr DL, Nussbaum DP, Kreulen RT, Somarelli JA, Blazer DG, et al. Soft tissue sarcoma of the extremities: What is the value of treating at high-volume centers? *Clinical orthopaedics and related research*. 2019;477(4):718-27.
  39. Schmitz R, Adam MA, Blazer DG, 3rd. Overcoming a travel burden to high-volume centers for treatment of retroperitoneal sarcomas is associated with improved survival. *World J Surg Oncol*. 2019;17(1):180.
  40. Stiles ZE, Dickson PV, Glazer ES, Murphy AJ, Davidoff AM, Behrman SW, et al. Desmoplastic small round cell tumor: A nationwide study of a rare sarcoma. *Journal of Surgical Oncology*. 2018;117(8):1759-67.
  41. Villano AM, Zeymo A, Chan KS, Shara N, Al-Refaie WB. Identifying the Minimum Volume Threshold for Retroperitoneal Soft Tissue Sarcoma Resection: Merging National Data with Consensus Expert Opinion. *Journal of the American College of Surgeons*. 2019.
  42. Villano AM, Zeymo A, McDermott J, Barrak D, Unger KR, Shara NM, et al. Regionalization of retroperitoneal sarcoma surgery to high-volume hospitals: Missed opportunities for outcome improvement. *Journal of Oncology Practice*. 2019;15(3):E247-E61.